CoChat

Response to high‐dose ifosfamide in patients with advanced/recurrent Ewing sarcoma

Ferrari, S., del Prever, A. Brach, Palmerini, E., Staals, E., Berta, M., Balladelli, A., Picci, P., Fagioli, F., Bacci, G., Vanel, D. · 2009 · Pediatric Blood & Cancer
Cited by 68

The DOI matches its Crossref record.

Abstract

Aim: To determine activity and toxicity of high‐dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods: Thirty‐seven EFT patients [median age 17 years (6–45 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m 2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results: Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty‐five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression. Conclusions: In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option. Pediatr Blood Cancer 2009;52:581–584. © 2009 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pbc.21917

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Ferrari, S., del Prever, A. B., Palmerini, E., Staals, E., Berta, M., Balladelli, A., Picci, P., Fagioli, F., Bacci, G., & Vanel, D.
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2009-01-13
Volume
52
Issue
5
Pages
581-584
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
OpenAlex
W2090650007
Cited by
68
References
0
FWCI
2.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.